SF
CRDL

Summit Financial’s Cardiol Therapeutics CRDL Stock Holding History

Summit Financial’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$105K Sell
99,109
-4,950
-5% -$6.26K ﹤0.01% 1561
2026
Q1 		$140K Hold
104,059
– – ﹤0.01% 1367
2025
Q4 		$99.3K Sell
104,059
-24,950
-19% -$26.1K ﹤0.01% 1272
2025
Q3 		$138K Buy
+129,009
New +$157K ﹤0.01% 1215

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $3.2B AUM 23.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Summit Financial's CRDL Position: Q2 2026 in Review

Summit Financial reduced its Cardiol Therapeutics (CRDL) stake by 4.8% in Q2 2026, selling an estimated $6.26K and leaving 99,109 shares worth $105K. The position accounts for ﹤0.01% of the portfolio, ranked #1561.

Summit Financial first reported a position in CRDL in Q3 2025 and has held it in 4 quarters since. The position peaked at $140K in Q1 2026. 51 funds tracked by Wall St. Rank hold CRDL as of Q2 2026.

  • Summit Financial held 99,109 shares of Cardiol Therapeutics worth $105K as of Q2 2026.
  • Summit Financial sold 4,950 Cardiol Therapeutics shares in Q2 2026, an estimated $6.26K.
  • Cardiol Therapeutics made up ﹤0.01% of Summit Financial's portfolio in Q2 2026, its #1561 holding.
  • Summit Financial first reported a position in Cardiol Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Summit Financial's Cardiol Therapeutics position peaked at $140K in Q1 2026.
  • 51 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q2 2026.

Based on Summit Financial's 13F filing for Q2 2026, filed 12 Aug 2026.